JPRN-UMIN000001857已完成1 期
A phase I study of cancer vaccine with NY-ESO-1 overlapping peptides in patients with advanced cancers expressing NY-ESO-1 antigen - Cancer vaccine with NY-ESO-1 overlapping peptides
Department of Immunology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences0 个研究点目标入组 9 人开始时间: 2009年4月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Clinically significant heart disease (i.e., NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias). 2.Other serious illnesses, e.g., serious infections requiring antibiotics, bleeding disorders. 3.Previous bone marrow or stem cell transplant. 4.History of immunodeficiency disease or autoimmune disease except vitiligo. 5.Metastatic disease to the central nervous system, unless treated and stable. 6.Other malignancy within 3 years prior to entry into the study, except for treated early-stage melanoma or non-melanoma skin cancer, or cervical carcinoma in situ. 7.Known HIV, positivity. 8.Concomitant treatment with steroids. Topical or inhalational steroids are permitted. (See also Section 6.7 for restrictions/recommendations on 'Ancillary Therapy'.) 9.Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent. 10.Pregnancy or lactation. 11.Women of childbearing potential not using a medically acceptable means of contraception. 12.Psychiatric or addictive disorders that may compromise the ability to give informed consent. 13.Lack of availability of the patient for immunological and clinical follow-up assessment.
研究者
相似试验
招募中
1 期
A phase Ia /Ib study of vaccination with NY-ESO-1 protein, Poly ICLC and mogamulizumab in patients with Adult T cell leukemia/lymphoma expressing NY-ESO-1 antigeAdult T cell Leukemia/LymphomaJPRN-UMIN000017748Osaka University Graduate School of Medicine30
已完成
1 期
A phase I clinical study of cancer vaccine with MAGE-A4/Survivin helper peptide for patients with advanced cancers expressing MAGE-A4 or Survivin antigeMAGE-A4- or Survivin-expressing refractory cancer patients (non origin-limited) or patients who refuse standard cancer therapyJPRN-UMIN000003489Department of General Surgery, Hokkaido University Graduated School of Medicine12
已完成
1 期
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil; OK-432 and Montanide; ISA-51 in patients with cancers expressing NY-ESO-1 antigeadvanced esophageal cancer, stomach cancer, non-small cell lung cancer (NSCLC), malignant melanomaJPRN-UMIN000001260Department of Immunology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences30
已完成
1 期
The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigeIntractable malignant tumors expressing MAGE-A4 antigenJPRN-UMIN000001999Department of Surgical Oncology, Hokkaido University Graduate School of Medicine18
已完成
1 期
A phase I study of vaccination with NY-ESO-1 protein mixed with Hiltonol(Poly ICLC), Picibanil(OK-432) and Montanide(ISA-51) in patients with cancers expressing NY-ESO-1 antigePatients with NY-ESO-1-expressing advanced esophageal cancer, gastric cancer, lung cancer and malignant melanomaJPRN-UMIN000007954Gastroenterological Surgery Osaka University Graduate School of Medicine15